Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tango TherapeuticsTNGX 54 Debt-to-EBITDA is -0.14 as of Jun. 2026. GuruFocus rates TNGX with a GF Score™ of 54/100 and a GF Value™ of $9.75 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 303 Biotechnology companies, Tango Therapeutics ranks worse than 330032.67% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Tango Therapeutics's Debt-to-EBITDA or its related term are showing as below:
TNGX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.38 Med: -0.28 Max: -0.03
Current: -0.24
During the past 6 years, the highest Debt-to-EBITDA Ratio of Tango Therapeutics was -0.03. The lowest was -0.38. And the median was -0.28.
TNGX's Debt-to-EBITDA is ranked worse than 100% of 303
companies
in the Biotechnology industry
Industry Median: 1.27
vs TNGX: -0.24
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Tango Therapeutics Debt-to-EBITDA Related Terms
Tango Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Tango Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TNGX vs IDYA, LEGN, DNLI: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Tango Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tango Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tango Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tango Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Tango Therapeutics (TNGX) has a Debt-to-EBITDA of -0.14 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Tango Therapeutics. According to the industry distribution chart, Tango Therapeutics ranks #999999 out of 303 companies in the Biotechnology industry.
Is Tango Therapeutics' Debt-to-EBITDA too high?
Tango Therapeutics' current Debt-to-EBITDA is -0.14. Based on the distribution chart, Tango Therapeutics ranks #999999 out of 303 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tango Therapeutics has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tango Therapeutics' Debt-to-EBITDA compare to IDYA and LEGN?
According to the Biotechnology industry distribution chart, Tango Therapeutics ranks #999999 out of 303 companies for Debt-to-EBITDA. This places Tango Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.27, based on 303 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Tango Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tango Therapeutics's current Debt-to-EBITDA is -0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tango Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Tango Therapeutics (TNGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.75, compared to a current price of $22.70 — trading 132.8% above its estimated fair value. The current Debt-to-EBITDA is -0.14. Tango Therapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Tango Therapeutics (TNGX), the current Debt-to-EBITDA is -0.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tango Therapeutics (TNGX) Overvalued in 2026?
Based on GuruFocus' analysis, Tango Therapeutics stock appears to be overvalued.
The current stock price of $22.70 is trading 132.8% above its estimated GF Value™ of $9.75.
GuruFocus considers Tango Therapeutics to be Significantly Overvalued.
Key valuation signals for TNGX:
Debt-to-EBITDA: -0.14
GF Value™: $9.75 vs. price of $22.70 (132.8% above fair value)
No single metric tells the full story. See the TNGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
54GF Score
Get the complete analysis for TNGX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNGX has been successfully added to your 
